Developmental Funds

发展基金：摘要 癌症中心支持补助金（CCSG）发展基金是至关重要的，以履行大学的使命。 佛罗里达健康癌症中心（UFHCC）。发展基金促进创新研究和战略 招聘符合中心的战略举措。自2016年以来，UFHCC在全球范围内开展合作， 佛罗里达大学在内部和外部招聘58个新的UFHCC成员（45个新的UF）， 其中39人（67%）是早期研究者（ESI），26人（45%）是女性，10人（17%）代表性不足 少数群体教师被招募到8个学院，为UFHCC贡献成员。在这些新兵中， 20人是肿瘤发生机制的成员，19人是癌症治疗和宿主反应的成员， 19个是癌症控制和人口科学，显示出在各个项目中的平均分布。UFHCC 承诺为所有招聘提供总计2990万美元的启动支持，迄今已支出1440万美元。这些新 UFHCC成员已经在合作方面为中心做出了重大贡献 项目和多机构研究、出版物和干预性临床试验。重要的是，由于 加入UF，这些新成员已经获得了56个新的同行评审的校外赠款总额为3900万美元（直接 成本），其中1480万美元（约38%）来自NCI。总的校外资金，包括转移赠款，归因于 这些新兵的直接费用为5240万美元，其中2420万美元（46%）由NCI提供。投资回报率 迄今为止，与所有校外同行审查资金（直接费用）相比， 招募比例>3.6：1。自2016年以来，UFHCC试点和探索性研究提案收到了183份提案， 审查，33%获得批准的资金。2016年至2020年授予的项目成果，其中 已经有足够的时间来评估影响（300万美元的试点资金），包括159份出版物和2000万美元（直接 成本，所有获奖年份）在新的校外同行评审的资金，投资回报率约为6.7：1。以来 2016年，发展基金协助扩大了UFHCC的资金组合。与新 招募，癌症相关资金总额从2016年的2100万美元增加到2021年的3260万美元（增长55%）直接成本， NCI资金从960万美元增加到1320万美元（增长37%）。整体研究生产力的 UFHCC从2016年的369篇增加到2021年的641篇（增长1. 7倍）。出版物的数量 影响≥10从2016年的59人增加到2021年的95人。自2016年以来，发展基金也支持招聘 18名开发新型干预性IIT的成员。2016年，IIT应计费用占 参加试验的受试者（占治疗累积的23%）。2021年，个人所得税应计项目占入学人数的91% (59%的治疗）。干预性试验应计项目从2016年的515项增加到2021年的1，748项（增长3. 4倍）。 治疗累计数从2016年的138项增加到2021年的299项（增长2. 2倍）。发展资金将用于 提供试点赠款，以鼓励与集水区有关的创新跨学科癌症科学，以及 在3个研究项目中招募高素质和多样化的新成员。

DEVELOPMENTAL FUNDS: ABSTRACT Cancer Center Support Grant (CCSG) Developmental Funds are critical to fulfill the mission of the University of Florida Health Cancer Center (UFHCC). Developmental Funds foster innovative research and strategic recruitment aligned with the Center's strategic initiatives. Since 2016, the UFHCC has collaborated across the University of Florida in the internal and external recruitment of 58 new UFHCC members (45 new to UF), of which 39 (67%) are early-stage investigators (ESIs), 26 (45%) are women, and 10 (17%) are underrepresented minorities. Faculty were recruited into 8 of the colleges that contribute members to the UFHCC. Of these recruits, 20 are members of Mechanisms of Oncogenesis, 19 are members of Cancer Therapeutics and Host Response, and 19 are in Cancer Control and Population Sciences, showing even distribution across the programs. UFHCC committed a total of $29.9M in start-up support for all recruitment, with $14.4M expended to date. These new UFHCC members have already made significant contributions to the center in terms of collaborative programmatic and multi-institutional research, publications, and interventional clinical trials. Importantly, since joining UF, these new members have obtained 56 new peer-reviewed extramural grants totaling $39M (direct costs), of which $14.8M (~38%) is from NCI. The total extramural funding, including transferred grants, attributed to these recruits is $52.4M (direct costs), with $24.2M (46%) awarded by the NCI. The return on investment on UFHCC recruitment expenses to date relative to all extramural peer-reviewed funding (direct costs) attributed to recruits is >3.6:1. Since 2016, the UFHCC Pilot and Exploratory Study Proposals received 183 proposals for review, with 33% approved for funding. Outcomes of projects awarded between 2016 and 2020, for which enough time had passed to assess impact ($3M of pilot funding), included 159 publications and $20M (direct costs, for all award years) in new extramural peer-reviewed funding, a return on investment ratio of ~6.7:1. Since 2016, Developmental Funds have assisted in the expansion of the UFHCC funding portfolio. With the new recruits, total cancer-relevant funding increased from $21M in 2016 to $32.6M in 2021 (up 55%) direct costs, NCI funding increasing from $9.6M to $13.2M (up 37%) direct costs. The overall research productivity of the UFHCC increased from 369 publications in 2016 to 641 in 2021 (up 1.7-fold). The number of publications with impact ≥10 went from 59 in 2016 to 95 in 2021. Since 2016, Developmental Funds also supported the recruitment of 18 members who developed novel interventional IITs. In 2016, accruals to IITs accounted for 70% of participants enrolled in trials (23% of treatment accruals). In 2021, IIT accruals accounted for 91% of enrollments (59% of treatment). Interventional trial accruals increased from 515 in 2016 to 1,748 in 2021 (up 3.4-fold). Treatment accruals increased from 138 in 2016 to 299 in 2021 (up 2.2-fold). Developmental funds will be used for pilot grants to encourage innovative transdisciplinary science on cancers relevant to the catchment area, and recruitment of highly qualified and diverse new members across the 3 research programs.